Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

370
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
370
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

131
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
131
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

185
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
185
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

169
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
169
Dialysis01:15

Dialysis

867
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
867
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

376
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
376

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

JAMA·2026
Same author

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Navigating Challenges and Adapting Innovations in Acute Kidney Injury and Kidney Failure.

Advances in kidney disease and health·2026
Same author

Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial.

American journal of nephrology·2026
Same author

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Kidney international reports·2025

Related Experiment Video

Updated: Oct 2, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.5K

Peritoneal dialysis fluids.

Sanmay Low1, Adrian Liew2

  • 1Division of Renal Medicine, Department of Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore.

Seminars in Dialysis
|February 25, 2022
PubMed
Summary
This summary is machine-generated.

Peritoneal dialysis (PD) fluids are crucial for kidney replacement therapy. Research focuses on improving PD fluid efficacy and biocompatibility, with icodextrin as a key alternative to glucose, though cost remains a barrier.

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.8K
Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion
06:23

Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion

Published on: May 23, 2025

692

Related Experiment Videos

Last Updated: Oct 2, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.5K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.8K
Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion
06:23

Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion

Published on: May 23, 2025

692

Area of Science:

  • Nephrology
  • Biomaterials Science

Background:

  • Peritoneal dialysis (PD) is a vital kidney replacement therapy with increasing global adoption.
  • PD fluids are essential for treatment efficacy, solute clearance, and ultrafiltration.
  • Current PD fluids face challenges in optimizing membrane health and minimizing systemic effects.

Purpose of the Study:

  • To review advances in peritoneal dialysis (PD) fluid development over the last 40 years.
  • To highlight the ongoing search for ideal PD fluid composition and alternative osmotic agents.
  • To discuss the impact of biocompatible PD fluids and barriers to their widespread use.

Main Methods:

  • Literature review of PD fluid evolution and research.
  • Analysis of glucose and alternative osmotic agents like icodextrin in PD fluids.
  • Evaluation of biocompatible PD fluids and their clinical implications.

Main Results:

  • Significant progress has been made in PD fluid understanding and formulation.
  • Glucose remains standard but has drawbacks, driving the use of alternatives like icodextrin.
  • Biocompatible fluids show promise for preserving kidney function but face cost and accessibility issues.

Conclusions:

  • Optimizing PD fluid composition is key to successful and individualized PD therapy.
  • Further large-scale clinical trials are needed to expand the range of available PD fluids.
  • Addressing cost and accessibility is crucial for broader adoption of advanced PD fluid technologies.